Patients with known hypersensitivity to any botulinum toxin product or to any of the components in the formulation.

Patients who have received botulinum toxin injections for any medical reason within 4 months prior to screening.

Patients with infection at proposed injection sites.

Patients scheduled for neurological or otological surgery for chronic ear disease, vestibular schwannoma, meningioma, or skull base tumors.

Significant psychiatric history or associated diagnosis of major depression.

Women who are pregnant or breastfeeding.

The Efficacy of Incobotulinum Toxin A Injections for Treatment of Tinnitus: a Randomized Controlled Trial